Multiple studies have shown that reduction of semaphorin 3A expression occurs in later stages of cancers (including breast and prostate) and that exogenous semaphorin 3A leads to reduced metastasis and angiogenesis (27, 52, 53, 54, 55, 56, 57). Here, SEMA3A is linked to cancer.